In-depth pieces from our trial team on Monsanto's defective product, the science behind the IARC classification, who qualifies for a Roundup lawsuit, and what makes our strict-product-liability approach different. Written by Alex Alvarez, Board Certified Civil Trial Lawyer, and Herb Borroto, M.D., J.D.
A Missouri court gave preliminary approval to a class settlement that sweeps in a “futures” subclass — people exposed to glyphosate before Feb. 17, 2026 who aren’t sick yet. What that does to your right to sue, what opting out preserves, and why the Supreme Court’s Amchem and Ortiz decisions make binding future victims so legally fragile.
Since 2023, consumer Roundup no longer contains glyphosate — the ingredient behind every cancer claim. Why Bayer swapped it out (in its own words, “exclusively to manage litigation risk”), why a claim looks back to the glyphosate product you actually used, and how the change fits the design-defect case after Durnell.
One large study found a clear link between heavy glyphosate use and non-Hodgkin lymphoma; another found none. A straight read of the human epidemiology — the Zhang meta-analysis, the North American Pooled Project’s DLBCL signal, the Agricultural Health Study’s null result, and IARC’s 2A call — and why, after Durnell, the science decides the case.
Most Roundup cases — and the largest verdicts — are in state court, not the federal MDL. Why the Durnell preemption ruling binds every courtroom, why it took away only the warning claim, and why the design-defect theory the big state verdicts were built on survived it.
After Durnell closed the failure-to-warn shortcut, a Roundup case rises or falls on the exposure record. What counts as proof, how it gets rebuilt when the receipts are long gone, how frequency and duration factor into causation, and what to preserve now.
The deadline that quietly ends more Roundup cases than any legal argument is your state’s statute of limitations. How the discovery rule decides when the clock starts, why old exposure rarely bars a claim on its own, what a statute of repose is, and why the Durnell ruling changes none of it.
Weeks after winning at the Supreme Court, Bayer asked Judge Chhabria to take apart the federal proceeding housing roughly 3,900 Roundup cases. What an MDL is, why “dismantling” it is not the same as ending the cases, why Bayer calls the survivors “repackaged warning claims,” and how the July 2026 status conference actually came out.
When the person who used Roundup has passed away, the right to hold Monsanto accountable does not die with them. The two claims a death creates — a survival action and a wrongful death claim — who can bring each, the separate deadline a death can start, and why design-defect survives both the loss and the Durnell ruling.
On July 2, 2026, Bayer folded its U.S. glyphosate business into a new subsidiary, Ruveon LLC, and analysts read it as a step toward an eventual spin-off. What a corporate reorganization does and doesn’t do to your claim — successor liability, fraudulent-transfer law, the ‘Texas two-step’ the courts rejected, and why nothing about a pending case changed.
A 2026 analysis found most heavy-glyphosate counties — and 82% of Iowa’s — have above-average non-Hodgkin lymphoma rates, echoing the March 2026 Seattle Statement. Why that pattern is real, and the ecological-fallacy reason a hot-spot map is never proof of an individual case.
Follicular lymphoma is the second most common non-Hodgkin lymphoma, often watched rather than treated, and frequently diagnosed years after exposure. That indolent course leads to two costly assumptions. What the B-cell science — and the litigation after Durnell — actually shows.
Roundup's most-cited defense — “the EPA says it doesn't cause cancer” — rests on a finding the Ninth Circuit vacated in 2022 as unsupported by substantial evidence. The EPA withdrew it and still hasn't finalized a replacement. What that unfinished record means after the Supreme Court's Durnell ruling.
The exposure group the headlines leave out: family who laundered an applicator's work clothes, bystanders present during spraying, and people who lived near treated land. What the take-home, biomonitoring, and NHL science shows — and how a non-applicator case is honestly evaluated.
Most coverage pictures farmers and landscapers. Here is how home and garden users are actually evaluated — the mixed science on residential use, the Hardeman verdict affirmed on appeal, product identification when the jugs are gone, and why the design-defect theory survived Durnell.
In 2026, the Supreme Court, Congress, and the White House were all asked to shield Bayer from Roundup claims. What the Durnell ruling, farm bill Section 10205, and Trump's glyphosate order each do — and the one theory none of them touches.
On June 25, 2026, the Court held 7-2 that FIFRA preempts state failure-to-warn claims. A plain-English read on what the ruling decided, which claims it did not touch, and why the design-defect theory we lead with still matters.
Bayer's approach has shaped how new cases are filed, evaluated, and litigated in 2026. Selective trial defense, structured resolution programs, and what the moving picture means for survivors considering a case.
MM is a plasma cell cancer with a documented agricultural-exposure signal. The CRAB criteria, the modern treatment paradigm, the AHS/IARC evidence base, and the chronic-disease damages picture.
CLL is the most common adult leukemia in the U.S. and one of the lymphoid cancers most consistently linked to glyphosate exposure. Diagnostic pattern, treatment landscape, and what cases need.
Professional landscapers and institutional groundskeepers had some of the highest occupational glyphosate exposure. What makes their cases distinctive.
DLBCL is the most common NHL in the U.S. and one of the cancers most strongly linked to glyphosate. What treatment looks like and how DLBCL cases get built.
What bellwethers are, what the Roundup bellwether record has demonstrated, and what the results mean for plaintiffs considering a case now.
Agricultural pesticide applicators had the highest documented exposures. The Agricultural Health Study, the Worker Protection Standard, and what makes farmworker cases distinctive.
How multi-product exposure histories affect cases. The post-2000 generic glyphosate market and what plaintiffs with mixed-product histories should know.
Non-Hodgkin Lymphoma is more than 60 distinct subtypes. DLBCL, Follicular, Mantle Cell, Marginal Zone, CLL/SLL — a plain-English map of which ones fit the science.
Non-Hodgkin Lymphoma gets the headlines. Multiple Myeloma is the underclaimed Roundup cancer — especially among farmers, groundskeepers, and commercial applicators. What the science shows and who qualifies.
What internal Monsanto documents reveal about ghost-writing, attacks on IARC, and how we use them to build cases.
Yes — new cases are still being filed. What Bayer's $10.9B settlement did and didn't resolve, and the statute-of-limitations clock you cannot let run out.
The World Health Organization's IARC calls glyphosate a probable carcinogen. The EPA does not. The reason matters in court.
Two roads to the same defendant. One is harder for Monsanto to escape. The same theory we used to win $100M+ from Big Tobacco.
Three exposure categories, four qualifying cancers, and what we need to evaluate your case — whether you sprayed the back forty or the back yard.
Free, confidential case review. Herb Borroto, M.D., J.D., reads your pathology personally. No fees unless we recover for you.
